Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Influenza Vaccines | 30 | 2021 | 2941 | 3.44 | Why? |
| Influenza, Human | 40 | 2021 | 10779 | 2.45 | Why? |
| Influenza A Virus, H3N2 Subtype | 9 | 2019 | 572 | 1.50 | Why? |
| Family Characteristics | 4 | 2021 | 2551 | 1.21 | Why? |
| Influenza B virus | 7 | 2020 | 815 | 0.87 | Why? |
| Michigan | 10 | 2021 | 988 | 0.78 | Why? |
| Neuraminidase | 4 | 2019 | 289 | 0.76 | Why? |
| Respiratory Tract Infections | 12 | 2020 | 6817 | 0.73 | Why? |
| Antigens, Surface | 1 | 2019 | 181 | 0.71 | Why? |
| Influenza A virus | 4 | 2019 | 2234 | 0.65 | Why? |
| Influenza A Virus, H1N1 Subtype | 8 | 2018 | 2984 | 0.58 | Why? |
| Likelihood Functions | 1 | 2017 | 719 | 0.57 | Why? |
| Oseltamivir | 1 | 2018 | 583 | 0.53 | Why? |
| Respiratory Syncytial Viruses | 2 | 2017 | 612 | 0.52 | Why? |
| Seasons | 13 | 2021 | 4071 | 0.50 | Why? |
| Antigens, Viral | 4 | 2019 | 6298 | 0.49 | Why? |
| Hemagglutination Inhibition Tests | 8 | 2019 | 191 | 0.47 | Why? |
| Respiratory Syncytial Virus Infections | 2 | 2017 | 1234 | 0.43 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 3 | 2019 | 511 | 0.41 | Why? |
| Vaccines, Attenuated | 4 | 2020 | 952 | 0.37 | Why? |
| Virus Diseases | 8 | 2020 | 3779 | 0.36 | Why? |
| Vaccination | 13 | 2021 | 19050 | 0.35 | Why? |
| Population Surveillance | 6 | 2018 | 4967 | 0.32 | Why? |
| World Health Organization | 2 | 2018 | 4213 | 0.29 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.29 | Why? |
| Antibody Formation | 2 | 2017 | 4038 | 0.27 | Why? |
| Orthomyxoviridae | 3 | 2020 | 1168 | 0.26 | Why? |
| Coronavirus | 2 | 2021 | 18339 | 0.22 | Why? |
| Vaccines, Inactivated | 4 | 2019 | 1562 | 0.22 | Why? |
| Adolescent | 26 | 2021 | 86841 | 0.21 | Why? |
| Stochastic Processes | 3 | 2018 | 369 | 0.21 | Why? |
| Models, Theoretical | 2 | 2017 | 6659 | 0.21 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.20 | Why? |
| Genetic Drift | 1 | 2019 | 54 | 0.20 | Why? |
| Child, Preschool | 16 | 2020 | 36283 | 0.19 | Why? |
| Antibodies, Viral | 8 | 2021 | 51949 | 0.18 | Why? |
| Child | 17 | 2020 | 70012 | 0.17 | Why? |
| Pneumonia | 1 | 2017 | 5652 | 0.17 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2021 | 12361 | 0.17 | Why? |
| Infant | 13 | 2020 | 30274 | 0.17 | Why? |
| Young Adult | 19 | 2021 | 93724 | 0.17 | Why? |
| Proportional Hazards Models | 2 | 2021 | 6543 | 0.16 | Why? |
| Epitopes | 2 | 2019 | 4113 | 0.16 | Why? |
| Public Health Surveillance | 3 | 2021 | 3129 | 0.15 | Why? |
| Cohort Studies | 6 | 2020 | 36005 | 0.15 | Why? |
| Humans | 55 | 2021 | 930598 | 0.15 | Why? |
| Maternal-Fetal Exchange | 1 | 2017 | 209 | 0.15 | Why? |
| Epidemiologic Methods | 2 | 2017 | 392 | 0.15 | Why? |
| Maternal Exposure | 1 | 2017 | 173 | 0.14 | Why? |
| Nasal Cavity | 1 | 2020 | 909 | 0.14 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.14 | Why? |
| Morbidity | 2 | 2018 | 1426 | 0.14 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.13 | Why? |
| Social Networking | 1 | 2020 | 737 | 0.13 | Why? |
| Adult | 28 | 2021 | 244371 | 0.13 | Why? |
| Frailty | 3 | 2019 | 1432 | 0.12 | Why? |
| Titrimetry | 1 | 2011 | 8 | 0.12 | Why? |
| Coinfection | 3 | 2021 | 6820 | 0.12 | Why? |
| History, 20th Century | 2 | 2017 | 1282 | 0.12 | Why? |
| Orthomyxoviridae Infections | 2 | 2019 | 1001 | 0.12 | Why? |
| Male | 31 | 2021 | 367725 | 0.12 | Why? |
| Female | 31 | 2021 | 380317 | 0.12 | Why? |
| Sentinel Surveillance | 1 | 2019 | 1093 | 0.12 | Why? |
| United States | 15 | 2021 | 46150 | 0.11 | Why? |
| Acute Disease | 5 | 2019 | 6029 | 0.11 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.11 | Why? |
| Antiviral Agents | 4 | 2018 | 41703 | 0.11 | Why? |
| Respiratory Tract Diseases | 1 | 2019 | 1061 | 0.11 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 13720 | 0.10 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.10 | Why? |
| Middle Aged | 22 | 2021 | 270681 | 0.10 | Why? |
| Medicare | 1 | 2017 | 1048 | 0.10 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.10 | Why? |
| Immune Evasion | 1 | 2018 | 2081 | 0.09 | Why? |
| Age Factors | 9 | 2019 | 21039 | 0.09 | Why? |
| Adjuvants, Immunologic | 1 | 2017 | 1709 | 0.08 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.08 | Why? |
| Serologic Tests | 2 | 2020 | 4359 | 0.08 | Why? |
| Coronaviridae | 3 | 1979 | 923 | 0.07 | Why? |
| Students | 2 | 2020 | 5255 | 0.07 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.07 | Why? |
| Aged | 15 | 2021 | 215776 | 0.07 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.07 | Why? |
| Prospective Studies | 3 | 2020 | 43301 | 0.07 | Why? |
| Evolution, Molecular | 1 | 2018 | 3691 | 0.07 | Why? |
| Coronavirus Infections | 3 | 2021 | 253789 | 0.06 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.06 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.06 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.06 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.06 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.06 | Why? |
| Hospitals | 2 | 2018 | 11793 | 0.05 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.05 | Why? |
| Bucladesine | 1 | 1979 | 2 | 0.05 | Why? |
| Israel | 2 | 2019 | 2751 | 0.05 | Why? |
| Virus Cultivation | 3 | 1979 | 579 | 0.05 | Why? |
| Infant, Newborn | 3 | 2020 | 23105 | 0.05 | Why? |
| Rubella Vaccine | 1 | 1999 | 17 | 0.05 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.05 | Why? |
| Zygote | 1 | 2018 | 10 | 0.05 | Why? |
| Mice | 1 | 2019 | 21357 | 0.05 | Why? |
| Immunization Schedule | 1 | 2006 | 1305 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| Neutralization Tests | 5 | 2020 | 6698 | 0.05 | Why? |
| Sequence Analysis, DNA | 2 | 2018 | 2830 | 0.05 | Why? |
| Vaccines, Synthetic | 2 | 2021 | 3231 | 0.05 | Why? |
| Chick Embryo | 1 | 2018 | 249 | 0.04 | Why? |
| Viral Proteins | 1 | 2017 | 7370 | 0.04 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.04 | Why? |
| Antigenic Variation | 1 | 2018 | 249 | 0.04 | Why? |
| Absenteeism | 1 | 2018 | 287 | 0.04 | Why? |
| Medical Records | 1 | 2019 | 513 | 0.04 | Why? |
| Immunologic Tests | 1 | 2019 | 445 | 0.04 | Why? |
| Hemagglutinins | 1 | 2017 | 143 | 0.04 | Why? |
| Placebos | 1 | 2019 | 629 | 0.04 | Why? |
| Antibodies | 3 | 2018 | 846 | 0.04 | Why? |
| Animals | 4 | 2020 | 78931 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2019 | 88759 | 0.04 | Why? |
| Patient Outcome Assessment | 1 | 2019 | 707 | 0.04 | Why? |
| Point Mutation | 1 | 2018 | 481 | 0.04 | Why? |
| Genome, Viral | 1 | 2017 | 13157 | 0.03 | Why? |
| Demography | 1 | 2021 | 1660 | 0.03 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.03 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.03 | Why? |
| Selection, Genetic | 1 | 2018 | 691 | 0.03 | Why? |
| Universities | 2 | 2020 | 4374 | 0.03 | Why? |
| Immune Sera | 1 | 2018 | 884 | 0.03 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.03 | Why? |
| Bronchitis | 1 | 1975 | 146 | 0.03 | Why? |
| Coronaviridae Infections | 1 | 1977 | 442 | 0.03 | Why? |
| Linear Models | 1 | 2019 | 1914 | 0.03 | Why? |
| Housing | 1 | 2020 | 1146 | 0.03 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.03 | Why? |
| Vaccination Coverage | 1 | 2021 | 1249 | 0.03 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2018 | 846 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.03 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.03 | Why? |
| Disease Outbreaks | 4 | 2006 | 27595 | 0.03 | Why? |
| Cost-Benefit Analysis | 1 | 2000 | 2259 | 0.03 | Why? |
| Complement Fixation Tests | 3 | 1974 | 7 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Interviews as Topic | 1 | 2018 | 1952 | 0.02 | Why? |
| Patient Readmission | 1 | 2018 | 1543 | 0.02 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.02 | Why? |
| Health Personnel | 1 | 2018 | 29646 | 0.02 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.02 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Comorbidity | 2 | 2019 | 34796 | 0.02 | Why? |
| Outpatients | 1 | 2018 | 3417 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3633 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Common Cold | 2 | 1985 | 645 | 0.02 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.02 | Why? |
| Models, Molecular | 1 | 2018 | 7616 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2019 | 4624 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.02 | Why? |
| RNA Viruses | 1 | 1970 | 824 | 0.02 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.02 | Why? |
| Inpatients | 1 | 2018 | 5161 | 0.01 | Why? |
| Benzimidazoles | 1 | 1985 | 275 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Serum Albumin, Bovine | 1 | 1979 | 40 | 0.01 | Why? |
| Vaccines | 1 | 1999 | 3692 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Washington | 1 | 1984 | 1722 | 0.01 | Why? |
| Nasopharynx | 1 | 2018 | 10224 | 0.01 | Why? |
| Blood | 1 | 1979 | 274 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Culture Media | 1 | 1979 | 366 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Mycoplasma Infections | 1 | 1975 | 65 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Fluorescent Antibody Technique | 1 | 1977 | 835 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Cell Line | 2 | 1979 | 12040 | 0.01 | Why? |
| Intensive Care Units | 1 | 2018 | 29594 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2018 | 25288 | 0.01 | Why? |
| Immunity, Active | 1 | 1970 | 31 | 0.01 | Why? |
| RNA, Viral | 1 | 2018 | 32276 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.01 | Why? |
| Sampling Studies | 1 | 1970 | 386 | 0.01 | Why? |
| Antibody Specificity | 1 | 1974 | 1328 | 0.01 | Why? |
| Coronary Disease | 1 | 1975 | 645 | 0.01 | Why? |
| Retrospective Studies | 1 | 2018 | 105322 | 0.00 | Why? |
| Species Specificity | 1 | 1970 | 1356 | 0.00 | Why? |
| Oximes | 1 | 1985 | 51 | 0.00 | Why? |
| Smoking | 1 | 1975 | 3358 | 0.00 | Why? |
| Chronic Disease | 1 | 1975 | 5139 | 0.00 | Why? |
| Quarantine | 1 | 2006 | 18418 | 0.00 | Why? |
| Rhinovirus | 1 | 1985 | 979 | 0.00 | Why? |
| Sex Factors | 1 | 1975 | 11014 | 0.00 | Why? |
| Sulfonamides | 1 | 1985 | 1294 | 0.00 | Why? |
| Double-Blind Method | 1 | 1985 | 5988 | 0.00 | Why? |
| Diabetes Mellitus | 1 | 1975 | 8207 | 0.00 | Why? |
| Clinical Trials as Topic | 1 | 1985 | 7330 | 0.00 | Why? |